SCHEMBL2331533

SCHEMBL2331533

COC(=O)Cc1cc(C(=O)O)c2cc(F)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.43
PLA2G2A P14555 3/20 0.41
CASP3 P42574 2/20 0.40
PRNP P04156 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
DHODH Q02127 4/20 0.39
ALDH1A1 P00352 4/20 0.39
GAA P10253 2/20 0.39
HSD17B10 Q99714 3/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
GFER P55789 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HK1 P19367 1/20 0.37
HKDC1 Q2TB90 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2171906 0.85 HSP90AB1 (0.50) HSP90AB1PLA2G2ACASP3PRNPMEN1
SCHEMBL3320334 0.83 KDM4E (0.42) HSP90AB1DHODHALDH1A1HSD17B10KDM4E
SCHEMBL2334076 0.81 MEN1 (0.48) HSP90AB1MEN1KMT2ADHODH
SCHEMBL11477653 0.80 HSP90AB1 (0.42) HSP90AB1PLA2G2ACASP3PRNPMEN1
SCHEMBL709951 0.79 PTGDR2 (0.44) PTGDR2
SCHEMBL708384 0.78 PTGDR2 (0.40) MEN1KMT2AALDH1A1GAAKDM4E
SCHEMBL11471175 0.78 GAA (0.51) HSP90AB1MEN1KMT2AALDH1A1GAA
SCHEMBL2174233 0.78 HSP90AB1 (0.49) HSP90AB1PLA2G2ACASP3PRNPMEN1
SCHEMBL2175029 0.78 LMNA (0.43) HSP90AB1PLA2G2ALMNAMAPT
SCHEMBL2175362 0.77 PTGDR2 (0.39) HSP90AB1CASP3PRNPCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-8188090-B2 Naphthylacetic acids HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188090-B2 Naphthylacetic acids HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188090-B2 Naphthylacetic acids HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
CN-102216273-A Naphthylacetic acids used as crth2 antagonists or partial agonists HOFFMANN LA ROCHE (CH) 2011-10-12 CN disclosed
EP-2358677-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. Hoffmann-La Roche AG (CH) 2011-08-24 EP disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125061-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 HSP90AB1 4432/4885PLA2G2A 866/4885CASP3 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.